[go: up one dir, main page]

WO2006040451A2 - Nouveaux derives de 9h-pyrido (2, 3-b) indole en tant qu'inhibiteurs de cdk et gsk3 , leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes - Google Patents

Nouveaux derives de 9h-pyrido (2, 3-b) indole en tant qu'inhibiteurs de cdk et gsk3 , leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes Download PDF

Info

Publication number
WO2006040451A2
WO2006040451A2 PCT/FR2005/002474 FR2005002474W WO2006040451A2 WO 2006040451 A2 WO2006040451 A2 WO 2006040451A2 FR 2005002474 W FR2005002474 W FR 2005002474W WO 2006040451 A2 WO2006040451 A2 WO 2006040451A2
Authority
WO
WIPO (PCT)
Prior art keywords
pyrido
novel
compounds
pharmaceutical compositions
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2005/002474
Other languages
English (en)
Other versions
WO2006040451A3 (fr
Inventor
Benoît JOSEPH
Laurent Meijer
François Liger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite Claude Bernard Lyon 1
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite Claude Bernard Lyon 1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite Claude Bernard Lyon 1 filed Critical Centre National de la Recherche Scientifique CNRS
Publication of WO2006040451A2 publication Critical patent/WO2006040451A2/fr
Publication of WO2006040451A3 publication Critical patent/WO2006040451A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des nouveaux dérivés de 9H-pyrido[2,3-b]indole, les compositions pharmaceutiques contenant de tels composés et leur utilisation pour la fabrication d'un médicament destiné au traitement ou à la prévention de cancers, de la maladie d'Alzheimer, de la maladie de Parkinson, d'accidents vasculaires cérébraux, de sclérose amyotrophique latérale (ALS), d'infections virales, de maladies auto-immunes, et de désordres neurodégénératifs.

Description


  --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> -->

Claims

--> --> --> --> --> -->
PCT/FR2005/002474 2004-10-11 2005-10-07 Nouveaux derives de 9h-pyrido (2, 3-b) indole en tant qu'inhibiteurs de cdk et gsk3 , leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes Ceased WO2006040451A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0410683 2004-10-11
FR0410683A FR2876377B1 (fr) 2004-10-11 2004-10-11 Nouveaux derives de 9h-pyrido[2,3-b]indole, leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes

Publications (2)

Publication Number Publication Date
WO2006040451A2 true WO2006040451A2 (fr) 2006-04-20
WO2006040451A3 WO2006040451A3 (fr) 2006-06-08

Family

ID=34952217

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2005/002474 Ceased WO2006040451A2 (fr) 2004-10-11 2005-10-07 Nouveaux derives de 9h-pyrido (2, 3-b) indole en tant qu'inhibiteurs de cdk et gsk3 , leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes

Country Status (2)

Country Link
FR (1) FR2876377B1 (fr)
WO (1) WO2006040451A2 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044779A1 (fr) * 2005-10-07 2007-04-19 Takeda San Diego, Inc. Inhibiteurs de kinase
WO2007149557A1 (fr) 2006-06-22 2007-12-27 Cephalon, Inc. [d]PYRIDAZIN-7-ONES CONDENSÉES
WO2008045834A3 (fr) * 2006-10-09 2008-07-24 Takeda San Diego Inc Inhibiteurs de kinases
CN101573335A (zh) * 2006-10-09 2009-11-04 武田药品工业株式会社 激酶抑制剂
JP2010505962A (ja) * 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP2223925A1 (fr) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase
US7935823B2 (en) 2007-09-20 2011-05-03 D2E, Llc Fluoro-containing derivatives of hydrogenated pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use
CN102203092A (zh) * 2008-09-08 2011-09-28 米兰-比科卡大学 NPM-ALK、RET和BCR-ABL的α-咔啉抑制剂
EP2662372A1 (fr) * 2012-05-11 2013-11-13 Università Degli Studi Di Milano - Bicocca Alpha-carbolines pour le traitement du cancer
WO2016037106A1 (fr) * 2014-09-05 2016-03-10 Allosteros Therapeutics, Inc Inhibiteurs camkii et leurs utilisations
US20170002005A1 (en) * 2014-01-21 2017-01-05 Ac Immune Sa Carbazole and Carboline Compounds for Use in the Diagnosis, Treatment, Alleviation or Prevention of Disorders Associated with Amyloid or Amyloid-Like Proteins
CN108218862A (zh) * 2018-02-07 2018-06-29 贵州医科大学 α-卡波林类衍生物在制备抗心肌缺氧复氧损伤药物中的应用
JP2019529401A (ja) * 2016-09-09 2019-10-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ２−（６−ニトロピリジン−３−イル）−９Ｈ−ジピリド［２，３−ｂ；３’，４’−ｄ］ピロールの製造方法
JP2023506215A (ja) * 2019-12-18 2023-02-15 ウニヴェルシテ ド モントリオール 抗がん性化合物としてのＣｕｌｌｉｎ３アダプタＫＢＴＢＤ４モジュレータ

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2079696A2 (fr) * 2006-10-09 2009-07-22 Takeda San Diego, Inc. Inhibiteurs de kinases
SG11202007143UA (en) 2018-01-31 2020-08-28 Heparegenix Gmbh Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US11731968B2 (en) 2018-06-21 2023-08-22 Heparegenix Gmbh Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
SG11202012732UA (en) 2018-07-16 2021-02-25 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
ES2984974T3 (es) 2020-01-15 2024-10-31 Heparegenix Gmbh Derivados de 3-benzoil-1H-pirrolo[2,3-b]piridina como inhibidores de MKK4 para el tratamiento de hepatopatías

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005137A1 (fr) * 1995-07-31 1997-02-13 Novo Nordisk A/S Composes heterocycliques, et preparation et utilisation de ces derniers
EP1388541A1 (fr) * 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines utilisées comme inhibiteurs de kinases
FR2846329B1 (fr) * 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8288536B2 (en) 2004-10-15 2012-10-16 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8318939B2 (en) 2005-10-07 2012-11-27 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP2133349A1 (fr) * 2005-10-07 2009-12-16 Takeda San Diego, Inc. Inhibiteurs de kinase
WO2007044779A1 (fr) * 2005-10-07 2007-04-19 Takeda San Diego, Inc. Inhibiteurs de kinase
EA015902B1 (ru) * 2005-10-07 2011-12-30 Такеда Фармасьютикал Компани Лимитед Ингибиторы киназ
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2007149557A1 (fr) 2006-06-22 2007-12-27 Cephalon, Inc. [d]PYRIDAZIN-7-ONES CONDENSÉES
CN101501038B (zh) * 2006-06-22 2012-07-18 赛福伦公司 稠合的[d]哒嗪-7-酮类化合物
CN101573335A (zh) * 2006-10-09 2009-11-04 武田药品工业株式会社 激酶抑制剂
JP2010505962A (ja) * 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
WO2008045834A3 (fr) * 2006-10-09 2008-07-24 Takeda San Diego Inc Inhibiteurs de kinases
EP2223925A1 (fr) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase
US8278450B2 (en) 2007-04-18 2012-10-02 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7935823B2 (en) 2007-09-20 2011-05-03 D2E, Llc Fluoro-containing derivatives of hydrogenated pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use
JP2012501984A (ja) * 2008-09-08 2012-01-26 ウニヴェルシダ’デリ ストゥディ ディ ミラノ−ビコッカ ＮＰＭ−ＡＬＫ、ＲＥＴおよびＢＣＲ−ＡＢＬのα−カルボリン阻害剤
CN102203092A (zh) * 2008-09-08 2011-09-28 米兰-比科卡大学 NPM-ALK、RET和BCR-ABL的α-咔啉抑制剂
EP2662372A1 (fr) * 2012-05-11 2013-11-13 Università Degli Studi Di Milano - Bicocca Alpha-carbolines pour le traitement du cancer
WO2013167730A1 (fr) * 2012-05-11 2013-11-14 Universita' Degli Studi Di Milano - Bicocca Alpha-carbolines pour le traitement du cancer
US9428500B2 (en) 2012-05-11 2016-08-30 Universita Degli Studi Di Milano—Bicocca Alpha-carbolines for the treatment of cancer
US10662193B2 (en) * 2014-01-21 2020-05-26 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins
US20170002005A1 (en) * 2014-01-21 2017-01-05 Ac Immune Sa Carbazole and Carboline Compounds for Use in the Diagnosis, Treatment, Alleviation or Prevention of Disorders Associated with Amyloid or Amyloid-Like Proteins
JP2017534572A (ja) * 2014-09-05 2017-11-24 アロステロス セラピューティクス， インコーポレイテッド ＣａＭＫＩＩ阻害剤及びその使用
CN107074856A (zh) * 2014-09-05 2017-08-18 阿略斯泰罗斯医疗公司 CaMKII抑制剂及其用途
WO2016037106A1 (fr) * 2014-09-05 2016-03-10 Allosteros Therapeutics, Inc Inhibiteurs camkii et leurs utilisations
US10759792B2 (en) 2014-09-05 2020-09-01 The Johns Hopkins University CaMKII inhibitors and uses thereof
JP2020143161A (ja) * 2014-09-05 2020-09-10 ザ・ジョンズ・ホプキンス・ユニバーシティー ＣａＭＫＩＩ阻害剤及びその使用
US11325908B2 (en) 2014-09-05 2022-05-10 The Johns Hopkins University CaMKII inhibitors and uses thereof
JP2019529401A (ja) * 2016-09-09 2019-10-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ２−（６−ニトロピリジン−３−イル）−９Ｈ−ジピリド［２，３−ｂ；３’，４’−ｄ］ピロールの製造方法
JP6997769B2 (ja) 2016-09-09 2022-02-10 エフ．ホフマン－ラ ロシュ アーゲー ２－（６－ニトロピリジン－３－イル）－９Ｈ－ジピリド［２，３－ｂ；３’，４’－ｄ］ピロールの製造方法
US11306093B2 (en) 2016-09-09 2022-04-19 Hoffmann-La Roche, Inc. Process for preparation of 2-(6-nitropyridin-3-yl)-9H-dipyrido[2,3-b;3′,4′-d]pyrrole
CN108218862A (zh) * 2018-02-07 2018-06-29 贵州医科大学 α-卡波林类衍生物在制备抗心肌缺氧复氧损伤药物中的应用
CN108218862B (zh) * 2018-02-07 2020-06-23 贵州医科大学 α-卡波林类衍生物在制备抗心肌缺氧复氧损伤药物中的应用
JP2023506215A (ja) * 2019-12-18 2023-02-15 ウニヴェルシテ ド モントリオール 抗がん性化合物としてのＣｕｌｌｉｎ３アダプタＫＢＴＢＤ４モジュレータ

Also Published As

Publication number Publication date
FR2876377A1 (fr) 2006-04-14
FR2876377B1 (fr) 2007-03-16
WO2006040451A3 (fr) 2006-06-08

Similar Documents

Publication Publication Date Title
WO2006040451A2 (fr) Nouveaux derives de 9h-pyrido (2, 3-b) indole en tant qu'inhibiteurs de cdk et gsk3 , leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes
WO2003053330A3 (fr) Nouveaux composés
CY1108514T1 (el) Παραγωγα 1-φαινυλαλκανεκαρβοξυλικου οξεος για τη θεραπεια νευρογενων ασθενειων
SI1427708T1 (sl) Derivati amino-ftalazinona kot zaviralci kinaze, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo
WO2003070236A3 (fr) Derives de pyrazole tricyclique, procedes de leur preparation et leur utilisation en tant qu'agents anti-tumoraux
WO2007100366A3 (fr) Modulateurs allostériques positifs du récepteur de la quinolone m1
WO2001098290A3 (fr) Derives de thiophene actifs en tant qu'inhibiteurs de kinase, leur procede de preparation, et compositions pharmaceutiques les contenant
WO2006035237A3 (fr) Procedes et compositions lies a la maladie d'alzheimer
TW200613305A (en) Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
WO2007127474A3 (fr) Compositions et traitements utilisant des pyridazines et des inhibiteurs de cholinestérase
WO2008002621A3 (fr) Effecteurs allostériques positifs du récepteur m1 à base de quinolone à substitution benzyle
MXPA05009719A (es) Derivados de biciclo-pirazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden.
AU2002359162A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
WO2005023833A3 (fr) Traitement de maladies neurodegeneratives
BRPI0411122A (pt) pirazol[3,4-b]piridin-6-onas como inibidores gsk-3
WO2005003103A3 (fr) Nouveaux heterocycles 2,4,6-trisubstitues et utilisations de ceux-ci
DK1181024T3 (da) Anvendelse af glycosaminoglycaner til behandling af senil demens
WO2006057945A3 (fr) Derives pyridyle 2,3,4,6-substitues utiles comme inhibiteurs de la beta-secretase pour le traitement de la maladie d'alzheimer
WO2009117283A3 (fr) Modulateurs allostériques positifs du récepteur m1 de la quinolizidine
ZA200700945B (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
WO2007017146A3 (fr) Utilisation de la collismycine et de derives de celle-ci comme inhibiteurs du stress oxydatif
WO2007019078A3 (fr) Inhibiteurs de la beta-secretase tricyclique pour traiter la maladie d'alzheimer
IL172229A (en) Use of pyrzolopyridines for the preparation of medicinal products to improve cognitive perception
WO2007019080A3 (fr) Inhibiteurs tricycliques de la beta-secretase pour le traitement de la maladie d'alzheimer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05809298

Country of ref document: EP

Kind code of ref document: A2